ALIGNMENT HEALTHC.DL-,001 Aktie

Alignment Healthcare reported second-quarter net income of $36.6 million, more than double year-ago levels, as medical costs for its Medicare Advantage members moderated. The company’s medical benefit ratio improved to about 86%, marking a second consecutive quarter of decline, while total revenue rose over 31% to $1.3 billion. Medicare Advantage membership grew 31% to 294,100 members. Management cited benefits from investments in clinical models, AI-enabled capabilities and operational infrastructure supporting profitable growth. » More on forbes.com

Shares of Alignment Healthcare recover after a roughly 17% drop following a whistleblower lawsuit, rising about 6% in midday trading. KeyBanc analyst Matthew Gillmor affirms an "overweight" rating and a $28 price target, calls the market reaction excessive and views the sell-off as a buying opportunity. Alignment categorically denied the allegations and points to a prior independent accounting review that found the claims unfounded. Support also came from a positive overall market and gains by competitors in the Medicare Advantage segment, while legal uncertainty limits a full recovery for now. » More on de.investing.com

A former executive is suing Alignment Healthcare, accusing the Medicare-Advantage provider of misclassifying expenses to inflate earnings and executive compensation. The stock fell sharply intraday, hitting a daily low of $19.52 after trading near multi-month highs earlier. The allegations create legal and reputational uncertainty ahead of the next quarterly report at the end of July, leaving investors unable to rely on new financial data in the short term. » More on de.investing.com